Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Rebello

Internal Medicine Delray Beach, FL Medical Doctor

NPI 1497728877 CMS profile 203512

13590 Jog Rd, Suite C3, Delray Beach, FL 33446

Open in the dashboard

General payments

$8,248

315 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Rebello of Delray Beach, FL is reported in the CMS Open Payments database as having received $8,248 across 315 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,978 53
2024 General $740 33
2023 General $895 39
2022 General $1,275 44
2021 General $982 57
2020 General $934 42
2019 General $1,443 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Rebello
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Brian Rebello were reported at $1,978. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Brian Rebello Internal Medicine median Middle half National median
2019 $1,443 $159 $48–$570 $163
2020 $934 $119 $33–$402 $114
2021 $982 $135 $37–$521 $132
2022 $1,275 $141 $42–$496 $149
2023 $895 $149 $45–$519 $160
2024 $740 $154 $47–$537 $164
2025 $1,978 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $757 30 payments
  2. Novo Nordisk Inc $670 29 payments
  3. Lilly USA, LLC $635 21 payments
  4. Amarin Pharma Inc. $605 31 payments
  5. AstraZeneca Pharmaceuticals LP $562 9 payments
  6. Novartis Pharmaceuticals Corporation $468 18 payments
  7. ITI, Inc. $425 12 payments
  8. Amgen Inc. $404 19 payments
  9. Merck Sharp & Dohme Corporation $305 16 payments
  10. Abbott Laboratories $265 6 payments
  11. Other $3,151 124 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,156 314 payments
  2. Education $92 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $553 18 payments
  2. Ozempic $428 19 payments
  3. Vascepa $420 26 payments
  4. CAPLYTA $404 11 payments
  5. RYBELSUS $369 17 payments
  6. TRULICITY $281 11 payments
  7. ENTRESTO $280 10 payments
  8. QULIPTA $271 8 payments
  9. DIFICID $269 14 payments
  10. Cologuard Collection Kit $256 9 payments
  11. Other $6,175 267 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 218 drugs

Part D claims

20,993

Median for Internal Medicine: 777

Drug cost

$1,717,236

Median for Internal Medicine: $73,373

Branded share of claims

15.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 201 $299,217
Eliquis Apixaban Brand 208 $235,792
Rybelsus Semaglutide Brand 53 $113,054
Jardiance Empagliflozin Brand 86 $110,442
Repatha Sureclick Evolocumab Brand 118 $93,747
Xarelto Rivaroxaban Brand 78 $89,205
Mounjaro Tirzepatide Brand 54 $69,554
Trulicity Dulaglutide Brand 35 $50,068
Januvia Sitagliptin Phosphate Brand 52 $47,348
Creon Lipase/Protease/Amylase Brand 23 $45,763

The 10 drugs with the highest cost, of 218 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$635,528

Of which drugs: $20,402

Medicare patients

1,438

Average age 81

Services billed

16,297

849 women, 589 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Ischemic heart disease 49%
Chronic kidney disease 43%
Diabetes 39%
Depression 36%
Atrial fibrillation 28%
Osteoporosis 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 514 515 $18,597
Vaccine for influenza for injection into muscle 90653 Office 19 19 $1,397
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 88 267 $256

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $40
$40 201 —
UBRELVY
  • AbbVie, Inc. $33
$33 17 —
QULIPTA
  • AbbVie, Inc. $33
$33 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $31
$31 — —
JARDIANCE
  • Lilly USA, LLC $29
$29 86 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

315 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record